Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · MDGL · as of Sep 30, 2025
Ownership Breakdown
383
Institutional Holders
▲ 51 vs Q2
$10.72B
Total Inst. Value
▲ $3.60B vs Q2
23.06M
Shares Outstanding
freeFloat 94.09%
23.39M
13F Shares Held
▼ 165,104 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
MDGL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 2.14M | 9.64% | 9.64% | $982.31B | Nov 14, 2025 | ▲ 165.7K |
RTW INVESTMENTS, LP pharmaceutical preparations | 1.99M | 8.98% | 8.98% | $914.42B | Nov 14, 2025 | — held |
PAULSON & CO. INC. pharmaceutical preparations | 1.91M | 8.59% | 8.59% | $874.90B | Nov 14, 2025 | ▼ 182.0K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.84M | 8.30% | 8.30% | $845.28B | Nov 14, 2025 | ▼ 349.1K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 1.83M | 8.25% | 8.25% | $840.72B | Nov 14, 2025 | ▼ 42.0K |
VANGUARD GROUP INC pharmaceutical preparations | 1.81M | 8.16% | 8.16% | $831.12B | Nov 7, 2025 | ▼ 65.2K |
BLACKROCK, INC. pharmaceutical preparations | 1.56M | 7.02% | 7.02% | $715.38B | Nov 12, 2025 | ▲ 121.0K |
STATE STREET CORP pharmaceutical preparations | 658.1K | 2.96% | 2.96% | $301.84B | Nov 14, 2025 | ▼ 32.6K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 446.2K | 2.01% | 2.01% | $204.70B | Nov 12, 2025 | ▲ 31.8K |
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC pharmaceutical preparations | 411.8K | 1.85% | 1.85% | $188.88B | Nov 12, 2025 | ▲ 61.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
21
Increased
+1.60M shares2
New Positions
first time holders23
Decreased
−1.81M shares0
Sold Out
fully exitedNet shares change (top 50)
212.8K
+1.60M / −1.81M
Net new holders
+0
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
MDGL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
14
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Soergel David Chief Medical Officer | Jun 1, 2026 | Sale | 1,042 | $495.74 | $516.6K | 10.0K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 40 | $506.68 | $20.3K | 27.7K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 320 | $508.24 | $162.6K | 27.3K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 151 | $510.36 | $77.1K | 27.2K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 610 | $511.40 | $312.0K | 26.6K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 439 | $512.50 | $225.0K | 26.1K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 40 | $512.97 | $20.5K | 26.1K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 343 | $514.67 | $176.5K | 25.8K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 657 | $515.92 | $339.0K | 25.1K | Form 4 ↗ |
Levy Richard S director | May 22, 2026 | Sale | 723 | $516.87 | $373.7K | 24.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Madrigal Pharmaceuticals, Inc. (MDGL) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 5.91%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Madrigal Pharmaceuticals, Inc. is BAKER BROS. ADVISORS LP, holding approximately 2.14 million shares — equal to 9.64% of outstanding shares — as of September 30, 2025.
A total of 383 institutional investors currently hold MDGL stock, with a combined institutional value of approximately $10.72 billion as of the most recent 13F filing period.
Frequently asked questions
MDGL ownershipMadrigal Pharmaceuticals, Inc. (MDGL) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 9.64% stake. Company insiders hold 5.91%. Data sourced from SEC Form 13F as of September 30, 2025.